Webmaster

[Auckland, New Zealand] — MAAB Group today announced the signing of a strategic licensing agreement to bring Sancuso® (granisetron transdermal system) across Greater China. Under the agreement, MAAB will assume exclusive manufacturing and commercialisation rights for Sancuso® in the region. The company plans to establish local production capacity in China to improve accessibility for patients and ensure a stable, cost-efficient supply chain.   Sancuso ® Relaunch Marks First Step of...

In the ever-evolving world of healthcare, having reliable access to high-quality reference medicines is essential for research,...